Evidence map›Paper›PMID 38589406›Full record

ArticleNature communications2024

Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.

Xinyu Bai, Grace H Attrill, Tuba N Gide, Peter M Ferguson, Kazi J Nahar, Ping Shang, Ismael A Vergara, Umaimainthan Palendira, Ines Pires da Silva, Matteo S Carlino and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Stratified analysis identifies HIF-2bioRxiv : the preprint server for biology · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Xinyu BaiMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-4212-1938
Grace H AttrillMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-8926-6582
Tuba N GideMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Peter M FergusonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-8335-0406
Kazi J NaharMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Ping ShangMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Ismael A VergaraMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-2960-2967
Umaimainthan PalendiraMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-1113-3306
Ines Pires da SilvaMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Matteo S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Georgina V Long *Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-8894-3545
Richard A Scolyer *Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-8991-0013
James S Wilmott *Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Camelia Quek *Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. camelia.quek@melanoma.org.au.ORCID http://orcid.org/0000-0002-1244-961X
The University of Sydney · AU

Funding

Cancer Institute NSW (Cancer Institute New South Wales) ECF1153
6 · The paper itself

Abstract

The biological underpinnings of therapeutic resistance to immune checkpoint inhibitors (ICI) in adolescent and young adult (AYA) melanoma patients are incompletely understood. Here, we characterize the immunogenomic profile and spatial architecture of the tumor microenvironment (TME) in AYA (aged ≤ 30 years) and older adult (aged 31-84 years) patients with melanoma, to determine the AYA-specific features associated with ICI treatment outcomes. We identify two ICI-resistant spatiotypes in AYA patients with melanoma showing stroma-infiltrating lymphocytes (SILs) that are distinct from the adult TME. The SIL

Indexed as

MelanomaAdolescentAgedHumansImmune Checkpoint InhibitorsImmune Checkpoint ProteinsImmunotherapyT-Lymphocytes, RegulatoryTumor MicroenvironmentYoung AdultImmune Checkpoint InhibitorsImmune Checkpoint Proteins

Identifiers

PMID38589406
PMCPMC11002019
OpenAlexW4394570667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.